MCID: PRS123
MIFTS: 40

Persistent Generalized Lymphadenopathy

Categories: Immune diseases

Aliases & Classifications for Persistent Generalized Lymphadenopathy

MalaCards integrated aliases for Persistent Generalized Lymphadenopathy:

Name: Persistent Generalized Lymphadenopathy 12 15
Persistant Generalized Lymphadenopathy 74
Pgl 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0060314
UMLS 74 C0856916

Summaries for Persistent Generalized Lymphadenopathy

Disease Ontology : 12 A lymph node disease characterized by enlarged, non-painful lymph nodes occurring for more than three to six months for which no other reason can be found.

MalaCards based summary : Persistent Generalized Lymphadenopathy, also known as persistant generalized lymphadenopathy, is related to paragangliomas 1 and hereditary paraganglioma-pheochromocytoma syndromes. An important gene associated with Persistent Generalized Lymphadenopathy is SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B), and among its related pathways/superpathways are Carbon metabolism and Pyruvate metabolism and Citric Acid (TCA) cycle. The drugs Emtricitabine and Darunavir have been mentioned in the context of this disorder. Affiliated tissues include lymph node, b cells and skin, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 77 Persistent generalized lymphadenopathy (PGL) is enlarged, painless, non-tender lymph nodes occurring in... more...

Related Diseases for Persistent Generalized Lymphadenopathy

Diseases related to Persistent Generalized Lymphadenopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Related Disease Score Top Affiliating Genes
1 paragangliomas 1 32.5 RET SDHB SDHC SDHD
2 hereditary paraganglioma-pheochromocytoma syndromes 30.8 RET SDHA SDHAF2 SDHB SDHC SDHD
3 paraganglioma 28.9 RET SDHA SDHAF2 SDHB SDHC SDHD
4 pheochromocytoma 28.0 EPAS1 RET SDHA SDHAF2 SDHB SDHC
5 6-phosphogluconolactonase deficiency 11.5
6 leprosy 3 10.6
7 hansen's disease 10.6
8 adrenal gland pheochromocytoma 10.3
9 c1q nephropathy 10.3 CD40LG CD79A
10 immunoglobulin g deficiency 10.3 CD40LG CD79A
11 cryofibrinogenemia 10.3 CD40LG CD79A
12 heparin-induced thrombocytopenia 10.3 CD40LG CD79A
13 immunoglobulin a deficiency 1 10.3 CD40LG CD79A
14 sporotrichosis 10.3 CD40LG CD79A
15 congenital syphilis 10.3 CD40LG CD79A
16 syphilis 10.3 CD40LG CD79A
17 secondary syphilis 10.3 CD40LG CD79A
18 immunodeficiency-centromeric instability-facial anomalies syndrome 1 10.3 CD40LG CD79A
19 ocular toxoplasmosis 10.3 CD40LG CD79A
20 immunodeficiency with hyper-igm, type 1 10.3 CD40LG CD79A
21 congenital toxoplasmosis 10.3 CD40LG CD79A
22 immunoglobulin alpha deficiency 10.2 CD40LG CD79A
23 cryptosporidiosis 10.2 CD40LG CD79A
24 pustulosis palmaris et plantaris 10.2 CD40LG CD79A
25 glomus tumor 10.2 SDHB SDHD
26 dysgerminoma of ovary 10.2 CD40LG CD79A
27 marginal zone b-cell lymphoma 10.2 CD40LG CD79A
28 lymphoma 10.2
29 agammaglobulinemia, x-linked 10.2 CD40LG CD79A
30 indeterminate leprosy 10.1
31 meningoencephalitis 10.1 CD40LG CD79A
32 cryoglobulinemia 10.1 CD40LG CD79A
33 seminal vesicle tumor 10.1 SDHA SDHB
34 chondroma 10.0 SDHB SDHC SDHD
35 immune deficiency disease 10.0 CD40LG CD79A
36 paraganglioma and gastric stromal sarcoma 10.0 SDHB SDHC SDHD
37 spastic quadriplegia 10.0 SDHA SDHD
38 quadriplegia 10.0 SDHA SDHD
39 renal cell carcinoma, nonpapillary 10.0
40 meningitis 10.0
41 glioma 10.0
42 tuberculous meningitis 10.0
43 multiple endocrine neoplasia, type iia 10.0 RET SDHB SDHD
44 acquired immunodeficiency syndrome 10.0
45 multiple endocrine neoplasia, type i 10.0 RET SDHB SDHD
46 autosomal genetic disease 10.0 RET SDHB SDHD
47 multiple endocrine neoplasia 9.9 RET SDHB SDHC
48 iga glomerulonephritis 9.9 CD40LG CD79A
49 beta-thalassemia 9.8
50 thalassemia 9.8

Graphical network of the top 20 diseases related to Persistent Generalized Lymphadenopathy:



Diseases related to Persistent Generalized Lymphadenopathy

Symptoms & Phenotypes for Persistent Generalized Lymphadenopathy

MGI Mouse Phenotypes related to Persistent Generalized Lymphadenopathy:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.56 CD40LG CD79A EPAS1 RET SDHB SDHC
2 homeostasis/metabolism MP:0005376 9.28 CD40LG CD79A EPAS1 RET SDHA SDHB

Drugs & Therapeutics for Persistent Generalized Lymphadenopathy

Drugs for Persistent Generalized Lymphadenopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 45)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2 143491-57-0 60877
2
Darunavir Approved Phase 4,Phase 3,Phase 2 206361-99-1, 635728-49-3 213039
3
Tenofovir Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2 147127-20-6 464205
4
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2 155213-67-5 392622
5
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2 134678-17-4 60825
6 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2
7 Anti-HIV Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2
9 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2
10
protease inhibitors Phase 4,Phase 3,Phase 2
11 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4,Phase 3
13 Reverse Transcriptase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Anti-Retroviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17
Abacavir Approved, Investigational Phase 3,Phase 2 136470-78-5 441300 65140
18
Dolutegravir Approved Phase 3,Phase 2 1051375-16-6 54726191
19
Efavirenz Approved, Investigational Phase 3,Phase 2 154598-52-4 64139
20
Lactitol Investigational Phase 3 585-88-6, 585-86-4 493591
21 Integrase Inhibitors Phase 3,Phase 2
22 HIV Integrase Inhibitors Phase 3,Phase 2
23 Raltegravir Potassium Phase 3,Phase 2
24 Dideoxynucleosides Phase 3
25 Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 3
26 Antimetabolites Phase 3,Phase 1,Not Applicable
27 Laxatives Phase 3
28 Cathartics Phase 3
29 Immunologic Factors Phase 3
30 Gastrointestinal Agents Phase 3
31 Vaccines Phase 3
32
Etravirine Approved Phase 2 269055-15-4 193962
33 Cytochrome P-450 CYP2C9 Inhibitors Phase 2
34 Cytochrome P-450 CYP2C19 Inhibitors Phase 2
35 Cytochrome P-450 CYP3A Inducers Phase 2
36
Zidovudine Approved Phase 1,Not Applicable 30516-87-1 35370
37
Aldesleukin Approved Phase 1 110942-02-4, 85898-30-2
38 Peripheral Nervous System Agents Phase 1
39 Analgesics, Non-Narcotic Phase 1
40 Analgesics Phase 1
41 Interleukin-2 Phase 1
42 Blood Substitutes Phase 1
43 Plasma Substitutes Phase 1
44 Dextrans Phase 1
45 Anticoagulants Phase 1

Interventional clinical trials:

(show all 17)
# Name Status NCT ID Phase Drugs
1 Darunavir/Ritonavir + Lamivudine Versus Darunavir/Ritonavir +Emtricitabine/Tenofovir in Naïve HIV-1 Infected Subjects Completed NCT02770508 Phase 4 darunavir/ritonavir;Lamivudine;emtricitabine-tenofovir(FTC/TDF)
2 Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects Completed NCT01449929 Phase 3 dolutegravir 50 mg OAD;darunavir 800mg OAD;ritonavir 100mg OAD
3 Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir Completed NCT01568892 Phase 3 Dolutegravir 50 mg twice daily;Dolutegravir placebo twice daily
4 A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen. Completed NCT01328041 Phase 3 dolutegravir
5 A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects Completed NCT01499199 Phase 3 Dolutegravir
6 A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial) Completed NCT01263015 Phase 3 Dolutegravir;Atripla;Abacavir/Lamivudine;Abacavir/Lamivudine Placebo;Dolutegravir placebo;Atripla placebo
7 A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Completed NCT01227824 Phase 3 GSK1349572 (dolutegravir);raltegravir
8 Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children Completed NCT01148459 Phase 3
9 A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults Active, not recruiting NCT01231516 Phase 3 GSK1349572;Raltegravir;GSK1349572 Placebo;Raltegravir Placebo
10 Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects Terminated NCT00197145 Phase 3 GW873140
11 A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir Completed NCT00950859 Phase 2 GSK1349572 (Cohort I);GSK1349572 (Cohort II)
12 A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects Completed NCT00951015 Phase 2 GSK1349572;efavirenz
13 Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection Terminated NCT01199731 Phase 2 GSK2248761 100 mg once daily;GSK2248761 200 mg once daily;Etravirine
14 Phase I Trial of the Combination of Zidovudine and Recombinant Interleukin-2 in Patients With Persistent Generalized Lymphadenopathy Completed NCT00000728 Phase 1 Zidovudine;Aldesleukin
15 A Study of AL721 in HIV-Infected Patients With Swollen Lymph Nodes Completed NCT00001012 Phase 1 AL 721
16 A Study of Dextran Sulfate in HIV-Infected Patients and in Patients With AIDS or AIDS Related Complex (ARC) Completed NCT00001009 Phase 1 Dextran sulfate
17 The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III) Completed NCT00002048 Not Applicable Zidovudine

Search NIH Clinical Center for Persistent Generalized Lymphadenopathy

Genetic Tests for Persistent Generalized Lymphadenopathy

Anatomical Context for Persistent Generalized Lymphadenopathy

MalaCards organs/tissues related to Persistent Generalized Lymphadenopathy:

42
Lymph Node, B Cells, Skin, T Cells, Monocytes, Ovary, Adrenal Gland

Publications for Persistent Generalized Lymphadenopathy

Articles related to Persistent Generalized Lymphadenopathy:

(show top 50) (show all 57)
# Title Authors Year
1
Persistent generalized lymphadenopathy (PGL) mimicking lymphoma on whole-body FDG PET/CT imaging. ( 16785807 )
2006
2
Persistent generalized lymphadenopathy and non-Hodgkin's lymphoma in AIDS: association with Rochalimaea henselae infection. ( 7496912 )
1994
3
Epstein-Barr virus and HIV play no direct role in persistent generalized lymphadenopathy syndrome. ( 1311993 )
1992
4
An open-label, dose-ranging trial of AL 721 in patients with persistent generalized lymphadenopathy and AIDS-related complex. ( 1890604 )
1991
5
Lymph nodes in HIV-positive drug abusers with persistent generalized lymphadenopathy: histology, immunohistochemistry, and pathogenetic correlations. ( 2103864 )
1990
6
Immunohistopathogenesis of persistent generalized lymphadenopathy in HIV-positive patients. ( 2192430 )
1990
7
Clinical manifestations of HIV infection, including persistent generalized lymphadenopathy and AIDS-related complex. ( 2193949 )
1990
8
Persistent generalized lymphadenopathy (transfusion-related) in an HIV-seropositive heterosexual man with sickle-cell beta-thalassemia. ( 2209816 )
1990
9
Ultrastructural analysis of germinal centers in lymph nodes of patients with HIV-1-induced persistent generalized lymphadenopathy: evidence for persistence of infection. ( 2491247 )
1989
10
Human immunodeficiency virus (HIV) and Epstein-Barr virus (EBV) antigens and genome in lymph nodes of HIV-positive patients affected by persistent generalized lymphadenopathy (PGL). ( 2556016 )
1989
11
The value of lymph node histology in human immunodeficiency virus related persistent generalized lymphadenopathy. ( 2736139 )
1989
12
Persistent generalized lymphadenopathy syndrome vs "AIDS"--unrelated malignant lymphoma: comparison of presenting clinical and laboratory findings in 88 patients. AIDS and Related Syndromes Study Group. ( 2773074 )
1989
13
Impaired T-lymphocyte-dependent immune responses to microbial antigens in patients with HIV-1-associated persistent generalized lymphadenopathy. ( 2902865 )
1988
14
Abnormal antibody responses in patients with persistent generalized lymphadenopathy. ( 2966810 )
1988
15
The pre-AIDS syndromes. Asymptomatic carriers, thrombocytopenic purpura, persistent generalized lymphadenopathy, and AIDS-related complex. ( 3060521 )
1988
16
Clinical and laboratory findings at presentation in persistent generalized lymphadenopathy vs malignant lymphoma. ( 3180127 )
1988
17
Paracortical immunoregulatory subpopulations in lymph nodes from homosexual men with persistent generalized lymphadenopathy. ( 3284806 )
1988
18
Elevated serum beta-2-microglobulin--a prognostic marker for development of AIDS among patients with persistent generalized lymphadenopathy. ( 3286507 )
1988
19
Subpopulations of CD4+ (T4+) cells in homosexual/bisexual men with persistent generalized lymphadenopathy. ( 2958183 )
1987
20
Flow cytometric lymphocyte immunophenotyping in homosexual men with the persistent generalized lymphadenopathy syndrome: a longitudinal study of lymph nodes and blood. ( 2962781 )
1987
21
Comparison of presenting clinical and laboratory findings of patients with persistent generalized lymphadenopathy (PGL) syndrome and malignant lymphoma (ML). ( 3126117 )
1987
22
Monoclonal antibodies to human immunodeficiency virus: their relation to the patterns of lymph node changes in persistent generalized lymphadenopathy and AIDS. ( 3130085 )
1987
23
Immunohistology of persistent generalized lymphadenopathy. Evidence for progressive lymph node abnormalities in some patients. ( 3300263 )
1987
24
Effect of subcutaneous thymopentin treatment in drug addicts with persistent generalized lymphadenopathy. ( 3301099 )
1987
25
Characterization of immunologic function in homosexual men with persistent, generalized lymphadenopathy and acquired immune deficiency syndrome. ( 3492262 )
1987
26
HLA-A, B and DR antigen frequencies in patients with AIDS-related persistent generalized lymphadenopathy (PGL) and thrombocytopenia. ( 3495904 )
1987
27
B-cell reactivity in homosexuals with persistent generalized lymphadenopathy (PGL). ( 3500784 )
1987
28
Progressive histopathologic abnormalities in the persistent generalized lymphadenopathy syndrome. ( 3618883 )
1987
29
Impaired anti-pneumococcal antibody response in patients with AIDS-related persistent generalized lymphadenopathy. ( 3652522 )
1987
30
Damage to secondary lymphoid follicles in AIDS-related persistent generalized lymphadenopathy, as revealed by the behaviour of dendritic reticulum cells possessing immunoreactive acid cysteine-proteinase inhibitor. ( 2870581 )
1986
31
Increase of OKT4+ cells during treatment with thymostimulin in parenteral drug addicts with persistent generalized lymphadenopathy. ( 2942692 )
1986
32
Surgical biopsy for persistent generalized lymphadenopathy. ( 3004631 )
1986
33
HTLV-III/LAV viral antigens in lymph nodes of homosexual men with persistent generalized lymphadenopathy and AIDS. ( 3008562 )
1986
34
Early warning skin signs in AIDS and persistent generalized lymphadenopathy. ( 3008802 )
1986
35
Serum beta-2 microglobulin levels in homosexual men with AIDS and with persistent, generalized lymphadenopathy. ( 3008977 )
1986
36
Altered functions of peripheral blood monocytes in homosexual males and intravenous drug users with persistent generalized lymphadenopathy. ( 3015636 )
1986
37
Immunologic studies in homosexual and hemophiliac subjects with persistent generalized lymphadenopathy: a comparative analysis. ( 3484760 )
1986
38
Persistent generalized lymphadenopathy in Northeastern Italy: increased frequency of HLA-DR 5. ( 3486498 )
1986
39
Lymphangiography and abdominal computerized tomography in persistent generalized lymphadenopathy. ( 3487330 )
1986
40
Persistent generalized lymphadenopathy: clinical characteristics of a lymphadenopathy syndrome in intravenous drug abusers. ( 3489471 )
1986
41
The immunohistology of the persistent generalized lymphadenopathy syndrome (PGL). ( 3491535 )
1986
42
Persistent generalized lymphadenopathy in drug addicts: immunological studies. ( 3539149 )
1986
43
A histopathologic study of persistent generalized lymphadenopathy in intravenous drug abusers. ( 3737476 )
1986
44
Persistent generalized lymphadenopathy: immunological and mycological investigations. ( 2420116 )
1985
45
Epstein-Barr virus infections in homosexual men with chronic, persistent generalized lymphadenopathy. ( 2982964 )
1985
46
The syndrome of persistent generalized lymphadenopathy: experience with 101 patients. ( 2994423 )
1985
47
Longitudinal assessment of persistent generalized lymphadenopathy (PGL) in homosexual men. ( 2994424 )
1985
48
Lymph node immunohistology in intravenous drug abusers with persistent generalized lymphadenopathy. ( 2996460 )
1985
49
Cytofluorographic analysis of lymph nodes from patients with the persistent generalized lymphadenopathy (PGL) syndrome. ( 3158464 )
1985
50
Evaluation of natural killer cell activity in patients with persistent generalized lymphadenopathy and acquired immunodeficiency syndrome. ( 3874030 )
1985

Variations for Persistent Generalized Lymphadenopathy

Expression for Persistent Generalized Lymphadenopathy

Search GEO for disease gene expression data for Persistent Generalized Lymphadenopathy.

Pathways for Persistent Generalized Lymphadenopathy

GO Terms for Persistent Generalized Lymphadenopathy

Cellular components related to Persistent Generalized Lymphadenopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrion GO:0005739 9.65 SDHA SDHAF2 SDHB SDHC SDHD
2 mitochondrial inner membrane GO:0005743 9.46 SDHA SDHB SDHC SDHD
3 respiratory chain complex II GO:0045273 8.96 SDHB SDHC
4 mitochondrial respiratory chain complex II, succinate dehydrogenase complex (ubiquinone) GO:0005749 8.92 SDHA SDHB SDHC SDHD

Biological processes related to Persistent Generalized Lymphadenopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 9.73 SDHA SDHB SDHC SDHD
2 aerobic respiration GO:0009060 9.4 SDHB SDHC
3 B cell proliferation GO:0042100 9.37 CD40LG CD79A
4 tricarboxylic acid cycle GO:0006099 9.35 SDHA SDHAF2 SDHB SDHC SDHD
5 electron transport chain GO:0022900 9.33 SDHA SDHB SDHC
6 respiratory electron transport chain GO:0022904 9.32 SDHA SDHB
7 succinate metabolic process GO:0006105 9.26 SDHA SDHB
8 mitochondrial electron transport, succinate to ubiquinone GO:0006121 8.92 SDHA SDHAF2 SDHC SDHD

Molecular functions related to Persistent Generalized Lymphadenopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 electron transfer activity GO:0009055 9.46 SDHA SDHB SDHC SDHD
2 oxidoreductase activity, acting on the CH-CH group of donors GO:0016627 9.32 SDHA SDHC
3 succinate dehydrogenase activity GO:0000104 9.26 SDHA SDHD
4 ubiquinone binding GO:0048039 8.96 SDHB SDHD
5 succinate dehydrogenase (ubiquinone) activity GO:0008177 8.92 SDHA SDHB SDHC SDHD

Sources for Persistent Generalized Lymphadenopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....